HROW - Harrow Health, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.05
-0.06 (-1.17%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.11
Open5.08
Bid4.81 x 900
Ask5.49 x 1000
Day's Range5.03 - 5.25
52 Week Range2.22 - 8.99
Volume122,906
Avg. Volume338,653
Market Cap127.088M
Beta (3Y Monthly)-0.98
PE Ratio (TTM)5.45
EPS (TTM)0.93
Earnings DateNov 11, 2019 - Nov 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.38
Trade prices are not sourced from all markets
  • Harrow Health Enters Oversold Territory
    Zacks7 days ago

    Harrow Health Enters Oversold Territory

    Harrow Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Business Wire11 days ago

    SHAREHOLDER ALERT: Investigation of Harrow Health Announced by Holzer & Holzer, LLC

    Holzer & Holzer, LLC is investigating whether certain statements made by Harrow Health, Inc. (“Harrow Health” or the “Company”) (HROW) complied with federal securities laws. On August 14, 2019, Harrow Health filed a form 10-Q with the SEC that disclosed its Park facility in California is required to surrender its California pharmacy license by August 27. The price of Harrow Health stock fell following the announcement.

  • Does Harrow Health, Inc.'s (NASDAQ:HROW) CEO Pay Matter?
    Simply Wall St.11 days ago

    Does Harrow Health, Inc.'s (NASDAQ:HROW) CEO Pay Matter?

    In 2012 Mark Baum was appointed CEO of Harrow Health, Inc. (NASDAQ:HROW). First, this article will compare CEO...

  • Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates
    Zacks12 days ago

    Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates

    Harrow (HROW) delivered earnings and revenue surprises of -50.00% and 7.67%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire12 days ago

    Harrow Health Announces Second Quarter 2019 Results

    NASHVILLE, Tenn., Aug. 14, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the second quarter 2019. Second Quarter 2019 and Other Recent Notable.

  • Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for
    Zacks19 days ago

    Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for

    Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire24 days ago

    Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Broad Spectrum Anti-Microbial Ophthalmic and Otic Therapeutics

    NASHVILLE, Tenn., Aug. 02, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today announced that its newly formed subsidiary, Stowe Pharmaceuticals, Inc., has entered into an.

  • GlobeNewswire26 days ago

    Harrow Health Announces Launch of Mayfield Pharmaceuticals

    NASHVILLE, Tenn., July 31, 2019 -- Harrow Health, Inc. (NASDAQ: HROW), today announced it has filed a Form 8-K with the Securities and Exchange Commission containing a.

  • GlobeNewswirelast month

    Harrow Health to Announce Second Quarter 2019 Financial Results on August 14, 2019

    Harrow Health, Inc. (HROW) today announced it will release second quarter 2019 financial results after the close of trading on Wednesday, August 14, 2019.  The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1:30 p.m. Pacific Daylight Time on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (844) 602-0380 for domestic callers or (862) 298-0970 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Harrow Health website by clicking here.  A dial in replay of the call will be available until September 14, 2019.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 51861.  The webcast replay will be available until November 14, 2019.

  • Do Insiders Own Shares In Harrow Health, Inc. (NASDAQ:HROW)?
    Simply Wall St.2 months ago

    Do Insiders Own Shares In Harrow Health, Inc. (NASDAQ:HROW)?

    Every investor in Harrow Health, Inc. (NASDAQ:HROW) should be aware of the most powerful shareholder groups. Insiders...

  • Amid Bay Area exodus, Nashville is rockin’
    American City Business Journals2 months ago

    Amid Bay Area exodus, Nashville is rockin’

    California Gov. Gavin Newsom took direct aim at Tennessee in a speech to the Bay Area business community last week — and for good reason. Tennessee is often lauded — and more importantly, increasingly selected — by California companies looking to expand operations or relocate their corporate headquarters altogether. The Volunteer State was selected today by San Francisco bookkeeping tech startup Pilot.com for a new division headquarters, which will create 450 jobs in Nashville.

  • GlobeNewswire2 months ago

    Harrow Health Adds Two Senior Executives to its Nashville Team

    NASHVILLE, Tenn., June 25, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it has promoted Dennis Saadeh, PharmD as its Chief of Formulation Strategy and has.

  • The city's newest public company wants to build a new industry in Nashville
    American City Business Journals2 months ago

    The city's newest public company wants to build a new industry in Nashville

    “If we can bring the right people and the right brains and build out the infrastructure, we think we can build the industry,” Harrow Health CEO Mark Baum said.

  • GlobeNewswire2 months ago

    Harrow Health, Inc to Locate Headquarters in Nashville, Tennessee

    Tennessee Governor, Bill Lee, Department of Economic and Community Development Commissioner Bob Rolfe and Harrow Health, Inc (HROW) announced today that the company will locate its headquarters operations in Nashville. The new facility will operate as the company’s headquarters and will house the company’s executive positions.

  • Publicly traded San Diego firm moving HQ to Nashville
    American City Business Journals2 months ago

    Publicly traded San Diego firm moving HQ to Nashville

    A publicly traded health care company is relocating from the West Coast to Nashville — but it won’t be the typical Middle Tennessee health care firm.

  • PR Newswire3 months ago

    Novel Drug Solutions, LLC and Eye Care Northwest, PA Terminates Agreement with Harrow Health, Inc.

    ROSELAND, N.J., May 30, 2019 /PRNewswire/ -- Axiom Communications, on behalf of Novel Drug Solutions, LLC and Eye Care Northwest, PA announced today that the companies have delivered a Notice of Termination and Cease and Desist directive to Harrow Health, Inc. (NASDAQ: HROW formerly known as Imprimis Pharmaceuticals, Inc.).

  • GlobeNewswire3 months ago

    Harrow Health Announces Renegotiated Debt Facility with SWK Holdings

    Harrow Health, Inc. (HROW) today announced it has amended its loan agreement with SWK Funding LLC and its partners.  SWK Funding LLC is a subsidiary of SWK Holdings Corporation, a healthcare-focused investment firm.

  • Associated Press4 months ago

    Harrow: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had profit of 43 cents. Losses, adjusted for non-recurring gains, came to 2 cents per share. The pharmaceutical and drug compounding company posted ...

  • GlobeNewswire4 months ago

    Harrow Health Announces First Quarter 2019 Financial Results

    The company’s management team will host a conference call and audio-only webcast today at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial results and other recent developments.  To participate in the call, please dial (844) 602-0380 for domestic callers or (862) 298-0970 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Harrow Health website by clicking here.  A dial in replay of the call will be available until June 9, 2019.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 48440.  The webcast replay will be available until August 9, 2019.

  • GlobeNewswire4 months ago

    Harrow Health to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

    SAN DIEGO, May 07, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company’s business.

  • GlobeNewswire4 months ago

    Harrow Health to Announce First Quarter 2019 Financial Results on May 9, 2019

    Harrow Health, Inc. (HROW) today announced it will release first quarter 2019 financial results after the close of trading on Thursday, May 9, 2019.  The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1:30 p.m. Pacific Daylight Time on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (844) 602-0380 for domestic callers or (862) 298-0970 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Harrow Health website by clicking here.  A dial in replay of the call will be available until June 9, 2019.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 48440.  The webcast replay will be available until August 9, 2019.

  • GlobeNewswire4 months ago

    ImprimisRx to Introduce New Formulations at Cataract & Refractive Surgery Annual Meeting

    ImprimisRx, the ophthalmology-focused pharmaceutical compounding subsidiary of Harrow Health, Inc. (HROW), today announced its participation at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held at the San Diego Convention Center in San Diego, CA May 3-7, 2019. With an estimated 11,000 attendees expected, this is the largest U.S. meeting of anterior segment surgeons, which integrates a scientific program dedicated to the needs of surgeons, specialists, practice management staff, and ophthalmic technicians and nurses.

  • Is Harrow Health's (NASDAQ:HROW) Share Price Gain Of 117% Well Earned?
    Simply Wall St.4 months ago

    Is Harrow Health's (NASDAQ:HROW) Share Price Gain Of 117% Well Earned?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It hasn't been the best quarter for Harrow Health, Inc. (NASDAQ:HROW) shareholders, since the...

  • Harrow Health, Inc. (NASDAQ:HROW) Delivered A Better ROE Than Its Industry
    Simply Wall St.5 months ago

    Harrow Health, Inc. (NASDAQ:HROW) Delivered A Better ROE Than Its Industry

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return OnRead More...

  • Associated Press5 months ago

    Harrow: 4Q Earnings Snapshot

    SAN DIEGO (AP) _ Harrow Health, Inc. (HROW) on Tuesday reported fourth-quarter net income of $18.1 million, after reporting a loss in the same period a year earlier. On a per-share basis, the San Diego-based company said it had net income of 77 cents. The pharmaceutical and drug compounding company posted revenue of $11.4 million in the period.